scholarly journals Is There a Clear Threshold for Fasting Plasma Glucose That Differentiates Between Those With and Without Neuropathy and Chronic Kidney Disease?: The Singapore Prospective Study Program

2009 ◽  
Vol 169 (12) ◽  
pp. 1454-1462 ◽  
Author(s):  
E. E. K. Nang ◽  
C. M. Khoo ◽  
E. S. Tai ◽  
S. C. Lim ◽  
S. Tavintharan ◽  
...  
2018 ◽  
Vol 146 ◽  
pp. 233-239 ◽  
Author(s):  
Tomomichi Koshi ◽  
Hiroyuki Sagesaka ◽  
Yuka Sato ◽  
Kazuko Hirabayashi ◽  
Hideo Koike ◽  
...  

2017 ◽  
Vol 20 (suppl 1) ◽  
pp. 90-101 ◽  
Author(s):  
Bruce Bartholow Duncan ◽  
Elisabeth Barboza França ◽  
Valéria Maria de Azeredo Passos ◽  
Ewerton Cousin ◽  
Lenice Harumi Ishitani ◽  
...  

ABSTRACT: Introduction and objective: The global burden of disease (GBD) 2015 project, extends GBD analyses to include Brazilian federative units separately. We take advantage of GBD methodological advances to describe the current burden of diabetes and hyperglycemia in Brazil. Methods: Using standard GBD 2015 methods, we analyzed the burden of diabetes, chronic kidney disease due to diabetes and high fasting plasma glucose in Brazil and its states. Results: The age-standardized rate of disability-adjusted life years (DALYs) which was lost to high fasting plasma glucose, a category which encompasses burdens of diabetes and of lesser hyperglycemia, were 2448.85 (95% UI 2165.96-2778.69) /100000 for males, and 1863.90 (95% UI 1648.18-2123.47) /100000 for females in 2015. This rate was more than twice as great in states with highest burden, these being overwhelmingly in the northeast and north, compared with those with lowest rates. The rate of crude DALYs for high fasting plasma glucose, increased by 35% since 1990, while DALYs due to all non-communicable diseases increased only by 12.7%, and DALYs from all causes declined by 20.5%. Discussion: The worldwide pandemic of diabetes and hyperglycemia now causes a major and growing disease burden in Brazil, especially in states with greater poverty and a lesser educational level. Conclusion: Diabetes and chronic kidney disease due to diabetes, as well as high fasting plasma glucose in general, currently constitute a major and growing public health problem in Brazil. Actions to date for their prevention and control have been slow considering the magnitude of this burden.


2014 ◽  
Vol 146 (5) ◽  
pp. S-477
Author(s):  
Diego Garcia-Compean ◽  
Joel O. Jaquez-Quintana ◽  
Fernando J. Lavalle-Gonzalez ◽  
Jose A Gonzalez ◽  
Linda E. Munoz-Espinosa ◽  
...  

2011 ◽  
Vol 86 (11) ◽  
pp. 1042-1049 ◽  
Author(s):  
Xuemei Sui ◽  
Carl J. Lavie ◽  
Steven P. Hooker ◽  
Duck-Chul Lee ◽  
Natalie Colabianchi ◽  
...  

2015 ◽  
Vol 41 (2) ◽  
pp. 107-115 ◽  
Author(s):  
Xiaobing Yang ◽  
Xin Lin ◽  
Tao Lu ◽  
Pingyan Chen ◽  
Xiaobin Wang ◽  
...  

Background/Aims: Glucocorticoids-induced abnormal glucose metabolism (AGM) is a common medical problem in patients with non-diabetic chronic kidney disease (CKD). However, little information is available regarding the prediction of steroid-induced AGM in this patient population. Methods: In this prospective cohort study, we consecutively enrolled 303 non-diabetic CKD patients with fasting plasma glucose (FPG) levels <5.6 mmol/l and normal oral glucose tolerance test (OGTT). OGTT was performed every 3 months during glucocorticoid treatment to identify new-onset AGM, and patients were followed for 12 months post steroid withdrawal. Results: During 593 person-years, there were 107 incident cases of steroid-induced AGM (18/100 person-year), including 55 (51.4%) diabetes and 52 (48.6%) pre-diabetes. In a multivariate model, each millimole increase per liter in FPG enhanced the risk of AGM by 4.6-fold (hazard ratio 4.58, 95% confidence interval, 2.67-7.83). After adjusting other risk factors, a progressively increased risk of AGM or DM was observed in patients with FPG levels ≥4.8 mmol/l, as compared with those whose levels were ≤4.3 mmol/l (p for trend <0.001). Furthermore, a greater increase in FPG level (≥0.3 mmol/l) during the first 3 months of glucocorticoid treatment was associated with an increased risk for future diabetes. For predicting steroid-induced diabetes, the area under the receiver-operating characteristic curve was 0.90 for the combination of FPG and changes in FPG levels at month 3. Conclusion: Higher-normal FPG and a greater increase in FPG levels during glucocorticoid treatment may help to identify non-diabetic CKD patients at increased risk of steroid-induced AGM or diabetes.


Sign in / Sign up

Export Citation Format

Share Document